tbuckley/cabot-search huggingface dataset:
Brain Metastases in Lung Cancer With Targetable Mutations
Authors: David M. Guttmann, Abigail T. Berman
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract P161: Conversion of Secreted High-Molecular-Weight FGF-2 to an 18 kDa Low-Molecular-Weight FGF-2 by Limited Proteolysis Suppresses the Paracrine Induction of Cardiomyocyte Hypertrophy
Authors: Jon-Jon R Santiago, Brian P Bestvater, Robert R Fandrich, Elissavet Kardami
Journal: Circulation Research (2011)

Background: High molecular weight, 23 kDa rat FGF-2 (Hi-FGF-2) is composed of an N-terminal extension as well as the 18 kDa core sequence present in low molecular weight (Lo-) FGF-2. Hi- and Lo-FGF-2 have distinct biological activities: unlike Lo-FGF-2, Hi-FGF-2, which is secreted by cardiac non-myocytes, promotes cardiomyocytes hypertrophy in vivo and in vitro . We tested if the paracrine pro-hypertrophic effects of secreted Hi-FGF-2 can be blunted by limited proteolysis of its N-terminal extension. Experimental: Heparin-sepharose-bound Hi-FGF-2 present in rat tissue extracts converted to an approximately 18 kDa protein (*Lo-FGF-2) through truncation of its N-terminal extension, in the absence of protease inhibitors. Serine protease inhibitors such as PMSF fully prevented this conversion. Similarly, purified recombinant rat Hi-FGF-2 was converted to *Lo-FGF-2 by thrombin, a serine protease, and the effect was prevented by hirudin, a thrombin specific inhibitor. Conditioned media from unstimulated or angiotensin II-stimulated rat cardiac non-myocytes (fibroblasts) were used to treat neonatal cardiomyocytes in culture, in the absence or presence of thrombin. Conditioned medium from stimulated (but not unstimulated) cells contained Hi-FGF-2, which promoted cardiomyocyte hypertrophy (increase in cell surface area), and the effect was due to secreted FGF-2 because it was prevented by neutralizing anti-FGF-2 antibodies. Thrombin itself had no effect on cell size but prevented the pro-hypertrophic effect of the conditioned media; while converting the secreted Hi-FGF-2 to *Lo-FGF-2. Conclusions: The truncation of the N-terminal extension of secreted Hi-FGF-2 by serine protease(s) can provide a strategy to prevent undesirable paracrine effects of Hi-FGF-2 (such as cardiac hypertrophy), while maintaining potentially beneficial (cytoprotective, angiogenic) effects associated with Lo-FGF-2.
Brote de parotiditis en Suecia, Febrero-Abril de 2004
Authors: B Sartorius, P Penttinen, J Nilsson, K Johansen, K Jönsson, M Arneborn, M Löfdahl, J Giesecke
Journal: Eurosurveillance (2005)

Entre el 24 de Febrero y el 26 de Abril de 2004 se notificaron 42 casos sospechosos de parotiditis en la region de Vastra Gotaland en Suecia. Se llevo a cabo un estudio descriptivo de los casos. Se realizo una encuesta telefonica y se calculo la efectividad vacunal mediante el metodo administrativo. De los 42 casos sospechosos, 31 (74 %) fueron entrevistados por telefono. Ocho de las 42 muestras de suero fueron positivas o indeterminadas frente a IgM de parotiditis por ELISA. En el 50 % (21/42) de las muestras de saliva se identifico el genoma del virus. De estas, se seleccionaron 11 para la secuenciacion y en todas se confirmo el virus de la parotiditis. Los casos procedian principalmente de dos pequenas ciudades. De los 19 casos que desarrollaron inflamacion bilateral, 18 estaban asociados a una ciudad pequena. La edad mediana de los casos encuestados fue de 43 anos (rango 5-88). De los seis casos que requirieron hospitalizacion, cinco eran mayores de 30 anos. La incidencia mas alta se produjo en el grupo de 35 a 44 anos. Se estimo una efectividad vacunal del 65 % para una dosis y del 91 % para dos dosis. Este estudio descriptivo muestra el numero creciente de casos de parotiditis con coberturas de vacunacion en aumento. La efectividad vacunal fue particularmente elevada para dos dosis. Se debe asegurar una buena cobertura para dos dosis, ya que los fallos de la vacuna primaria en parotiditis estan bien documentados. Se deben de tomar grandes precauciones para evitar bolsas de individuos susceptibles de edades adultas, debido al mayor riesgo de complicaciones.
Optimizing fresh specimen staining for rapid identification of tumor biomarkers during surgery
Authors: Connor W. Barth, Jasmin M. Schaefer, Vincent M. Rossi, Scott C. Davis, Summer L. Gibbs
Journal: Theranostics (2017)

Rationale: Positive margin status due to incomplete removal of tumor tissue during breast conserving surgery (BCS) is a prevalent diagnosis usually requiring a second surgical procedure.These follow-up procedures increase the risk of morbidity and delay the use of adjuvant therapy; thus, significant efforts are underway to develop new intraoperative strategies for margin assessment to eliminate re-excision procedures.One strategy under development uses topical application of dual probe staining and a fluorescence imaging strategy termed dual probe difference specimen imaging (DDSI).DDSI uses a receptor-targeted fluorescent probe and an untargeted, spectrally-distinct fluorescent companion imaging agent topically applied to fresh resected specimens, where the fluorescence from each probe is imaged and a normalized difference image is computed to identify tumor-target distribution in the specimen margins.While previous reports suggested this approach is a promising new tool for surgical guidance, advancing the approach into the clinic requires methodical protocol optimization and further validation.Methods: In the present study, we used breast cancer xenografts and receiver operator characteristic (ROC) curve analysis to evaluate a wide range of staining and imaging parameters, and completed a prospective validation study on multiple tumor phenotypes with different target expression.Imaging fluorophore-probe pair, concentration, and incubation times were systematically optimized using n=6 tissue specimen replicates per staining condition.Resulting tumor vs. normal adipose tissue diagnostic performance were reported and staining patterns were validated via receptor specific immunohistochemistry colocalization.Optimal staining conditions were tested in receptor positive and receptor negative cohorts to confirm specificity.Results: The optimal staining conditions were found to be a one minute stain in a 200 nM probe solution (area under the curve (AUC) = 0.97), where the choice of fluorescent label combination did not significantly affect the diagnostic performance.Using an optimal threshold value determined from ROC curve analysis on a training data set, a prospective study on xenografts resulted in an AUC=0.95 for receptor positive tumors and an AUC = 0.50 for receptor negative (control) tumors, confirming the diagnostic performance of this novel imaging technique.Conclusions: DDSI provides a robust, molecularly specific imaging methodology for identifying tumor tissue over benign mammary adipose tissue.Using a dual probe imaging strategy, nonspecific accumulation of targeted probe was corrected for and tumor vs. normal tissue diagnostic potential was improved, circumventing difficulties with ex vivo tissue specimen staining and allowing for rapid clinical translation of this promising technology for tumor margin detection during BCS procedures.
TCT-710 One-year Clinical Outcomes of Japanese Patients with Deferral of Coronary Intervention Based on Fractional Flow Reserve in Multicenter Registry: An Interim Analysis of the J-CONFIRM Registry
Authors: Shoichi Kuramitsu, Hitoshi Matsuo, Hiroaki Takashima, Nobuhiro Tanaka, Hiroyoshi Yokoi
Journal: Journal of the American College of Cardiology (2017)
TCT-358 Procedural Outcomes With New-Generation Transcatheter Aortic Valve Devices in Real-World Clinical Practice: The PRAGMATIC-II (Pooled Rotterdam – Milan – Toulouse in Collaboration) Study
Authors: Gennaro Giustino, Didier Tchetche, Nicolas Van Mieghem, Nicolas Dumonteil, Raphael Philippart, Nahid El Faquir, Chiara De Biase, Zouhair Rahhab, Peter P.T. De Jaegere, Antonio Colombo, Alaide Chieffo
Journal: Journal of the American College of Cardiology (2017)
Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
Authors: Michaela Tsai, Shelly Lo, William Audeh, Rubina Qamar, Raye Budway, Ellis Levine, Pat Whitworth, Blanche Mavromatis, Robin Zon, Dwight Oldham, Sarah Untch, Tina Treece, Lisa Blumencranz, Hatem Soliman
Journal: JAMA Oncology (2017)

Among patients who undergo the 21-gene assay (21-GA), 39% to 67% receive an intermediate risk result and may receive ambiguous treatment guidance. The 70-gene signature assay (70-GS) may be associated with physicians' treatment decisions in this population with early breast cancer.To determine whether 70-GS findings are associated with physicians' decisions about adjuvant treatment and confidence in their recommendations and to evaluate the dichotomous (high- vs low-risk) and continuous distribution of 70-GS indices among this group of patients with intermediate risk.The Prospective Study of MammaPrint in Breast Cancer Patients With an Intermediate Recurrence Score (PROMIS trial) was an impact study conducted from May 20, 2012, through December 31, 2015, that enrolled 840 patients with early-stage breast cancer and a 21-gene assay recurrence score of 18 to 30. Patients were treated in 58 US institutions.The 70-GS result was given to physicians before adjuvant treatment.Change in physician treatment decision before vs after receiving the 70-GS result. With a treatment change of greater than 20%, the odds ratio (OR) was applied.Among the 840 patients who underwent 70-GS classification (mean age, 59 years; range, 27-93 years), 374 (44.5%) had a low-risk and 466 (55.5%) had a high-risk result. The distribution of 70-GS indices did not correlate with recurrence score within the 21-GA intermediate range, with 70-GS low- and high-risk patients observed at every recurrence score. A significant change in adjuvant treatment was associated with receiving the 70-GS classifications with an OR of 0.64 (95% CI, 0.50-0.82; McNemar test, P < .001) for all patients. Among the low-risk patients, 108 of 374 (28.9%) had chemotherapy removed from their treatment recommendation; among the high-risk patients, 171 of 466 (36.7%) had chemotherapy added. Results of the 70-GS were associated with the physician's adjuvant treatment recommendation; 409 high-risk patients (87.8%) were recommended to receive adjuvant chemotherapy, and 339 low-risk patients (90.6%) were recommended no chemotherapy. Physicians reported having greater confidence in their treatment recommendation in 660 cases (78.6%) based on 70-GS results.The 70-GS provides clinically actionable information regarding patients classified as intermediate risk by the 21-GA and was associated with a change in treatment decision in 282 of these patients (33.6%). Chemotherapy was added or withheld by the treating physician based on the results of the 70-GS test. Physicians reported more confidence with their treatment recommendation after receiving 70-GS results.
Synergistic anticancer activity of EGCG with cancer preventive agents mediated through GADD153 gene expression in human lung cancer cells
Authors: Masami Suganuma, Miki Kurusu, Kaoru Suzuki, Hirota Fujiki
Journal: Cancer Research (2006)

3173  We first reported the synergistic induction of apoptosis in human lung cancer cell line PC-9 by cotreatment with green tea polyphenol, (-)-epigallocatechin gallate (EGCG) and cancer preventive agents, such as sulindac and tamoxifen. We further confirmed the synergistic induction of apoptosis and apoptosis-related gene expression, such as GADD153 gene, in human lung cancer cells by cotreatment with EGCG plus celecoxib. In particular, induction of apoptosis and GADD153 gene expression were strong with EGCG plus celecoxib, while neither EGCG nor celecoxib alone was effective. However, expression of other apoptosis-related genes, notably GADD45 gene and p21WAF1 gene, was not induced by cotreatment. Cotreatment with EGCG plus celecoxib mechanistically activated ERK1/2 and p38MAPK, but not JNK. The ERK inhibitors PD98059 and UO126 abrogated both up-regulation of GADD153 gene and induction of apoptosis, but a p38MAPK inhibitor, SB203580, did not, indicating that GADD153 gene expression is mediated through the ERK signaling pathway. Synergistic effects of EGCG and celecoxib on induction of apoptosis and GADD153 gene expression were also observed in two other lung cancer cell lines, A549 and ChagoK-1. These results indicate that GADD153 gene product plays a significant role in synergistic induc tion of apoptosis in cells. In addition to anti-estrogenic agents and COX-2 inhibitors, we also found that synergistic induction of GADD153 gene expression and apoptosis was observed in the combination of EGCG plus all-trans-retinoic acid (ATRA) and 9-cis-retinoic acid (9-cis-RA), but not with N-(4-hydroxyphenyl)retinamide (4HPR), since 4HPR alone induced both activities. The results indicate that all the cancer preventive agents previously studied, such as sulindac, celecoxib, ATRA and 9-cis-RA, need to be reinvestigated in the presence of EGCG and/or green tea extract using GADD 153 gene expression as a biomaker of cancer preventive activity in humans.
TCT-148 10-Year Clinical Outcomes of an Early Invasive Versus a Selective Strategy in Patients Non-ST-segment Elevation Acute Coronary Syndrome With Diabetes Mellitus: A Subgroup Analysis of the ICTUS Trial
Authors: Niels Hoedemaker, Peter Damman, Pier Woudstra, Alexander Hirsch, Jan Tijssen, Robbert de Winter
Journal: Journal of the American College of Cardiology (2017)
Cardiac Magnetic Resonance Myocardial Perfusion After Arterial Switch for Transposition of Great Arteries
Authors: Francesca Raimondi, Giovanni Donato Aquaro, Daniele De Marchi, Camilla Sandrini, Diala Khraiche, Pierluigi Festa, Lamia Ait Ali, Nathalie Boddaert, Damien Bonnet
Journal: JACC. Cardiovascular imaging (2017)
TCT-60 Stent Versus Non-Stent Strategies For Endovascular Treatment of Femoropopliteal Peripheral Artery Disease: Insights From the XLPAD Registry
Authors: Micah Steinbrecher, Bo Sun, Ehrin Armstrong, Haekyung Jeon-Slaughter, Nicolas W. Shammas, Khusrow Niazi, Scott Kinlay, Mazen Abu-Fadel, Anand Prasad, Houman Khalili, Mujtaba Ali, Bala Ramanan, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2017)
SAT0034 Antinuclear antibodies in psoriatic arthritis
Authors: MM Silva, JV Patto, J Figueirinhas, MJ Mediavilla
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> It is usually believed that Antinuclear Antibodies are no more prevalent in psoriatic patients than in the general population. <h3>Objectives</h3> To assess the prevalence of ANA positivity in a group of psoriatic arthritis patients. To search for possible differences between those who are ANA positive and those who aren't. <h3>Methods</h3> We prospectively analysed according to a designed protocol 47 consecutive patients observed between 00/01/19 and 00/11/14. We recorded the history and physical examination with standard procedures. In all patients the presence of ANA and serum markers of viral hepatitis B and C were determined. <h3>Results</h3> We found 38,3% of ANA positivity (Group 1 = ANA positive patients; Group 2 = ANA negative patients). The majority of group 1 patients presented a speckled pattern in title equal or superior to 1/320. The two groups were similar in respect to gender distribution, age, duration of psoriasis, duration of arthritis, history of concomitant exacerbation of cutaneous and articular disease, history of previous or actual medication with sulphasalazine, extent of cutaneous involvement, presence of nail and scalp psoriasis and prevalence of viral hepatitis B and C. A greater frequency of sacroiliitis (50% vs 27,6%), of family history of psoriasis (61,1% vs 48,3%) and family history of psoriatic arthritis (22,2% vs 6,9%) was seen in group 1 but didn't reach statistical significance. <h3>Conclusion</h3> Our group of psoriatic arthritis patients shows a high prevalence of ANA positivity. Although the frequency of patients with sacroiliitis, family history of psoriasis and psoriatic arthritis is greater in the ANA positive group we were not able to show differences with statistical significance.
Prevalencia de infección por VIH-2 en Europa
Authors: F Cazein, F F Hamers, J Alix, J B Brunet
Journal: Eurosurveillance (1996)

La pandemia de infeccion por VIH y de SIDA esta essencialmente ligada al VIH-1. Existe otro tipo de virus, VIH-2 que se encuentra fundamentalmente en ciertos paises del africa occidental (1-5). En Europa, la mayoria de los casos descritos de infeccion por VIH-2 han sido en personas procedentes de Africa (6). El objetivo de este estudio es examinar la prevalencia de infeccion por VIH-2 en distintos paises europeos, y compararla con la seroprevalencia de infeccion por VIH-1 en las poblaciones testadas.
Type I IFN Receptor Signaling Controls IL7-Dependent Accumulation and Activity of Protumoral IL17A-Producing γδT Cells in Breast Cancer
Authors: Emmanuel C. Patin, Daphnée Soulard, Sébastien Fleury, Maya Hassane, David Dombrowicz, Christelle Faveeuw, François Trottein, Christophe Paget
Journal: Cancer Research (2017)

The protumoral activity of γδT17 cells has recently emerged in a wide variety of solid malignancies, including breast cancer. These cells exert their detrimental functions by promoting tumor growth, angiogenesis, and subsequent metastasis development. However, the intratumoral factors that regulate the biology of γδT17cells within the tumor microenvironment are less well understood. Here, using two experimental models of breast cancer, we reinforced the concept that tumor-infiltrating γδT17 cells are endowed with protumoral functions, which promote tumor progression and metastasis development. More importantly, we demonstrated a critical role for type I IFN signaling in controlling the preferential accumulation in the tumor bed of a peculiar subset of γδT17 cells displaying a CD27- CD3bright phenotype (previously associated with the invariant Vγ6Vδ1+ TCR). Interestingly, this effect was indirect and partially relied on the IFNAR1-dependent control of IL7 secretion, a factor that triggers proliferation and activating functions of deleterious γδT17 cells. Our work therefore identifies a key role of the type I IFN/IL7 axis in the regulation of intratumoral γδT17-cell functions and in the development of primary breast tumor growth and metastasis.Significance: Tumor-derived IL7 can represent a therapeutic target to prevent accumulation of immune cells endowed with potent protumoral activities. Cancer Res; 78(1); 195-204. ©2017 AACR.
PS02.10 Pneumonitis as a Complication of anti-PD/PDL1 Immunotherapy: A Meta-Analysis of Randomized Clinical Trials
Authors: M. Rahouma, M. Baudo, M. Yahia, M. Kamel, G. Ghaly, A.A. Abouarab, A.N. Cheriat, N. Abdel Karim, A. Mohamed, M. Gaudino
Journal: Journal of Thoracic Oncology (2017)
TCT-500 JCTO and PROGRESS CTO Scores Performance in Predicting Technical and Procedural Success after CTO PCI: An analysis of the OPEN CTO Multicenter Registry
Authors: Matthew Finn, Sanjog Kalra, Ajay Jayant Kirtane, Ziad Ali, Yuanyuan Tang, James Sapontis, John Spertus, Mohammed Qintar, Jeffrey Moses, Manish Parikh, J. Aaron Grantham, Dimitri Karmpaliotis
Journal: Journal of the American College of Cardiology (2017)
Europe steps up action against vaccine hesitancy as measles outbreaks continue
Authors: Rebecca Coombes
Journal: BMJ (2017)

The goal of eliminating measles from Europe was dealt a blow last week after new data showed how outbreaks continue to sweep the continent.

Nearly 19 000 cases of measles were reported in the European Union between January 2016 and October 2017, including 44 deaths, show figures collected by the European Centre for Disease Prevention and Control.1

The new figures were released as the centre steps up its initiatives in response to a rise in so called “vaccine hesitancy” in Europe. Speaking to The BMJ , the centre’s director, Andrea Ammon, said that governments and doctors needed to engage head on with parents over safety concerns. She praised Denmark, where rates of human papillomavirus (HPV) vaccination have plummeted, for taking its message to social media in a campaign that is showing some early promise.

“Safety is the most important determinant in deciding whether to vaccinate or not,” said Ammon. “People’s perception of …
Biomarkers in atopic dermatitis
Authors: Daphne Bakker, Marjolein de Bruin-Weller, Julia Drylewicz, Femke van Wijk, Judith Thijs
Journal: Journal of Allergy and Clinical Immunology (2023)

Atopic dermatitis (AD) is a complex and highly heterogeneous inflammatory skin disease. Given the highly heterogeneous character of AD, it is unlikely that every patient will respond equally to a particular treatment. The recent introduction of novel targeted therapies for AD has driven the need for patient stratification based on immunologic biomarkers. We have reviewed the use of different types of biomarkers as potential tools in the movement toward personalized medicine in AD, comprising different ways of endotyping patients with AD based on immunologic profiles and predictive biomarkers. The application of biomarkers will result in better characterization and stratification of patients and allow better comparison of current and new treatments. The ultimate goal will be to switch from the current generalized "one-drug-fits-all" management to more personalized "patient endotype-specific" management.